OnKure director Liam Ratcliffe files Form 3

OnKure Therapeutics, Inc. director Liam Ratcliffe filed a Form 3 insider ownership report for the company.

Accepted by SEC EDGAR 04/01/2026 - 05:24 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. director Liam Ratcliffe filed a Form 3 insider ownership report for the company. The data provided show no reported purchases, sales, option exercises, gifts, or other insider transactions, indicating this filing is purely an initial ownership disclosure without trading activity.

Key Terms

Form 3, reporting person, transaction summary

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

""reportingPersons": [{"name": "Ratcliffe Liam""

transaction summary financial

""transactionSummary": {"buyCount": 0, "sellCount": 0"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for OKUR and Liam Ratcliffe show?

The Form 3 for OnKure Therapeutics (OKUR) identifies Liam Ratcliffe as a director and reporting person. It lists no insider purchases, sales, option exercises, gifts, or other transactions, making it a baseline ownership disclosure rather than a trading event.

Did Liam Ratcliffe buy or sell OKUR shares in this Form 3?

No. The Form 3 data show zero buy and zero sell transactions for OnKure Therapeutics (OKUR). All transaction counts, including purchases, sales, exercises, gifts, and restructurings, are reported as zero in the transaction summary for this filing.

What role does Liam Ratcliffe have at OnKure Therapeutics (OKUR)?

In this filing, Liam Ratcliffe is identified as a director of OnKure Therapeutics (OKUR). He is not listed as an officer or ten-percent owner, and the Form 3 serves to register him as a reporting person under insider ownership rules.

Are there any derivative securities reported for OKUR in this Form 3?

No derivative securities are listed for OnKure Therapeutics (OKUR) in this Form 3. The derivative summary is empty and the transaction summary shows zero derivative transactions, indicating no options, warrants, or similar instruments are detailed in the provided data.

Does this OKUR Form 3 indicate any planned trading activity?

The Form 3 information provided does not indicate any trading activity or planned transactions for OnKure Therapeutics (OKUR). All transaction-related counts are zero, and there are no descriptive footnotes outlining trading plans or Rule 10b5-1 arrangements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ratcliffe Liam

(Last) (First) (Middle)

C/O ONKURE THEREAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/31/2026

3. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Rogan Nunn, by power of attorney	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)